{
  "created_at": "Sun Sep 26 19:57:39 +0000 2021",
  "id_str": "1442212393140961282",
  "full_text": "AstraZeneca said its breast cancer drug Enhertu significantly reduced the risk of dying or disease progression in women with advanced disease in a large clinical trial https://t.co/gtj2ggLv29",
  "display_text_range": [
    0,
    191
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/gtj2ggLv29",
        "expanded_url": "https://on.wsj.com/3kGp9jJ",
        "display_url": "on.wsj.com/3kGp9jJ",
        "indices": [
          168,
          191
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 33,
  "favorite_count": 146,
  "possibly_sensitive": false,
  "original_created_at": "Sun Sep 26 19:40:04 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "AstraZeneca社は、乳がん治療薬Enhertuが、大規模臨床試験において、病状が進行した女性の死亡または病状の進行のリスクを有意に減少させたと発表した https://t.co/gtj2ggLv29"
    },
    {
      "locale": "zh",
      "full_text": "阿斯利康表示，其乳腺癌药物Enhertu在一项大型临床试验中显著降低了晚期妇女死亡或疾病进展的风险https://t.co/gtj2ggLv29"
    },
    {
      "locale": "zh-Hant",
      "full_text": "阿斯利康表示，其乳腺癌藥物Enhertu在一項大型臨牀試驗中顯著降低了晚期婦女死亡或疾病進展的風險https://t.co/gtj2ggLv29"
    }
  ]
}